References
Bladé J, Kyle RA, Greipp PR (1996) Presenting features and prognosis in 72 patients with multiple myeloma who were younger than 40 years. Br J Haematol 93:345–351 doi:10.1046/j.1365-2141.1996.5191061.x
Dimopoulos MA, Hamilos G (2002) Solitary bone plasmacytoma and extramedullary plasmacytoma. Curr Treat Options Oncol 3:255 doi:10.1007/s11864-002-0015-2
Dytfeld D, Matuszak M, Lewandowski K, Komarnicki M (2008) Bortezomib in combination with thalidomide and dexamethasone—a successful treatment regimen in refractory extramedullary multiple myeloma. Ann Hematol 87:253–254 doi:10.1007/s00277-007-0401-8
Laura R, Cibeira MT, Uriburu C et al (2006) Bortezomib: an effective agent in extramedullary disease in multiple myeloma. Eur J Haematol 76:405–408 doi:10.1111/j.0902-4441.2005.t01-1-EJH2462.x
Richardson PG, Barlogie B, Berenson J et al (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609–2617 doi:10.1056/NEJMoa030288
Dilek I, Ayakta H, Demir C et al (2005) CA 125 levels in patients with non-Hodgkin lymphoma and other hematologic malignancies. Clin Lab Haematol 27:51–55 doi:10.1111/j.1365-2257.2004.00655.x
Iwasaki T, Hamano T, Aizawa K et al (1997) Increased serum CA 125 levels in plasma cell dyscrasias. Acta Haematol 98:104–108
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hwang, Y.Y., Chim, C.S., Chan, G. et al. Breast and pelvic masses in a myeloma patient. Ann Hematol 87, 1027–1029 (2008). https://doi.org/10.1007/s00277-008-0522-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-008-0522-8